|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600119385 |
|
最近更新日期: Date of Last Refreshed on: |
2026-02-26 10:57:49 |
|
注册时间: Date of Registration: |
2026-02-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中国儿童HFrEF的GDMT应用与疗效的前瞻性多中心队列研究 |
|
Public title: |
A Prospective, Multicenter Cohort Study on Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction in Chinese Children: Application and Efficacy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中国儿童HFrEF的GDMT应用与疗效的前瞻性多中心队列研究 |
|
Scientific title: |
A Prospective, Multicenter Cohort Study on Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction in Chinese Children: Application and Efficacy |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
田杰 |
研究负责人: |
田杰 |
|
Applicant: |
Jie Tian |
Study leader: |
Jie Tian |
|
申请注册联系人电话: Applicant telephone: |
+86 23 6363 3496 |
研究负责人电话:
Study leader's |
+86 23 6363 3496 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yuanyuxing@stu.cqmu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
jieetian@cqmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市渝中区中山二路136号 |
研究负责人通讯地址: |
重庆市渝中区中山二路136号 |
|
Applicant address: |
No. 136, Zhongshan 2nd Road, Yuzhong District, Chongqing |
Study leader's address: |
No. 136, Zhongshan 2nd Road, Yuzhong District, Chongqing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
重庆医科大学附属儿童医院 |
||
|
Applicant's institution: |
The Children's Hospital of Chongqing Medical University |
||
|
研究负责人所在单位: |
重庆医科大学附属儿童医院 |
||
|
Affiliation of the Leader: |
Children's Hospital of Chongqing Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2025)年伦审(临研)批件第(492)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
重庆医科大学附属儿童医院医学研究伦理委员会 |
||
|
Name of the ethic committee: |
Institutional Review Board Children's Hospital of Chongqing Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-12-08 00:00:00 | ||
|
伦理委员会联系人: |
蔡诗容 |
||
|
Contact Name of the ethic committee: |
Shirong Cai |
||
|
伦理委员会联系地址: |
重庆市渝中区中山二路136号 |
||
|
Contact Address of the ethic committee: |
No. 136, Zhongshan 2nd Road, Yuzhong District, Chongqing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 68370035 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
741223671@qq.com |
|
研究实施负责(组长)单位: |
重庆医科大学附属儿童医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Children's Hospital of Chongqing Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市渝中区中山二路136号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 136, Zhongshan 2nd Road, Yuzhong District, Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家儿童健康与疾病临床医学研究中心临床医学研究重点项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
The Key Grant from the National Clinical Research Center for Child Health and Disorders |
||||||||||||||||||||||
|
研究疾病: |
心力衰竭 |
||||||||||||||||||||||
|
Target disease: |
Heart failure |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
主要目标: 评估我国伴收缩功能障碍(LVEF<50%)的慢性心衰儿童中,指南推荐的药物治疗(GDMT)的真实世界使用模式,包括启动时机、联用顺序、剂量滴定模式及达标情况。 次要目标: 记录药物治疗相关的不良反应、停药及剂量下调事件,分析儿童心衰患者对GDMT的耐受性及安全性; 探讨影响GDMT实施效果的关键因素,包括年龄、病因、合并症、家庭及社会经济因素; 评估患儿的临床预后,包括LVEF、NYHA/ROSS心功能状态、全因死亡率、心衰再住院率、心脏移植或机械循环支持发生率等。 |
||||||||||||||||||||||
|
Objectives of Study: |
Primary Objective: To evaluate the real-world utilization patterns of Guideline-Directed Medical Therapy (GDMT) in Chinese children with chronic heart failure and systolic dysfunction (LVEF <50%). This assessment will include the timing of initiation, sequencing of combination, dose titration patterns, and the achievement of target doses. Secondary Objectives: To document drug-related adverse events, treatment discontinuations, and dose reduction events, and to analyze the tolerability and safety profile of GDMT in pediatric heart failure patients. To investigate key factors influencing the implementation and effectiveness of GDMT, including age, etiology of heart failure, comorbidities, as well as familial and socioeconomic factors. To assess clinical outcomes in the pediatric cohort, including changes in Left Ventricular Ejection Fraction (LVEF), NYHA/ROSS functional class status, all-cause mortality, heart failure rehospitalization rate, and the incidence of cardiac transplantation or mechanical circulatory support. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.18岁以下的慢性心衰患儿,诊断标准参照2025年ISHLT儿童心衰指南及2020中国儿童心衰诊疗建议; 2.经超声心动图证实存在左心室收缩功能障碍(LVEF<50%),并计划启动GDMT治疗者; 3.入组后至少1年内能在就诊单位规律复诊; 4.患儿或法定监护人签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Pediatric patients under 18 years of age with chronic heart failure, diagnosed according to the 2025 International Society for Heart and Lung Transplantation (ISHLT) Guidelines for Pediatric Heart Failure and the 2020 Chinese Recommendations for the Diagnosis and Management of Pediatric Heart Failure. 2. Presence of left ventricular systolic dysfunction (LVEF <50%) confirmed by echocardiography, and scheduled to initiate Guideline-Directed Medical Therapy (GDMT). 3. Ability to adhere to regular follow-up visits at the participating clinical site for at least one year post-enrollment. 4. Written informed consent provided by the patient and/or their legal guardian. |
||||||||||||||||||||||
|
排除标准: |
1.预期生存期小于3个月,或3月内计划心脏移植; 2.合并严重影响随访或数据质量的疾病(如活动性恶性肿瘤、严重神经系统残疾无法配合); 3.对GDMT药物过敏或禁忌(如严重肝肾功能不全); 4.研究者判断不适合参与本研究的其他情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Life expectancy of less than 3 months, or planned cardiac transplantation within 3 months. 2. Comorbid conditions that would significantly compromise follow-up adherence or data quality (e.g., active malignancy, severe neurological disability precluding cooperation). 3. Known allergy or contraindication to GDMT medications (e.g., severe hepatic or renal dysfunction). 4. Any other condition which, in the judgment of the investigator, would make the patient unsuitable for participation in this study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2029-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-03-01 00:00:00 至 To 2028-03-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
团队计划在三年内构建儿童心衰的管理平台,数据将同步至该在线平台。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Our team plans to establish a dedicated pediatric heart failure registry and management platform within three years. All research data will be integrated into this centralized online system. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集和管理由两部分组成,一为基于“问卷星”系统的问卷采集,二为电子采集和管理系统。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The data acquisition and management framework comprises two integrated components: Questionnaire-Based Data Collection: Utilizing the "Wenjuanxing" platform for electronic patient-reported and clinician-reported outcomes. Electronic Data Capture (EDC) System: A structured electronic system for the comprehensive collection, storage, and management of all clinical and research data. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |